Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
RESPONSE TO AMENDMENT
Status of Application/Amendments/claims
2. Applicant’s amendment filed April 21, 2026 is acknowledged. Claims 1-33 are canceled. Claims 34 and 51 are amended. Claims 34-58 are pending in this application. Claims 40-50 and 53-58 are withdrawn without traverse (filed 09/24/2025) from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Upon reconsideration, the species election of different sequences of SEQ ID NOs: 72, 74 and 76 for a heavy chain and different sequences of SEQ ID NOs: 60, 63 and 68 for a heavy chain constant region is withdrawn. The subject matter to the extent of SEQ ID NOs: 72 and 76, and SEQ ID NOs: 60 and 68 is included and under examination in this office action. Election was made without traverse in the reply filed on September 24, 205.
3. Claims 34-39 and 51-52 are under examination in this office action.
4. Applicant’s arguments filed on April 21, 2026 have been fully considered but they are not deemed to be persuasive for the reasons set forth below.
Drawings
5. The objection to Figures 1A-1B is withdrawn in response to Applicant’s amendment to the specification.
Claim Rejections/Objections Withdrawn
6. The objection to claims 34-39 and 51-52 is withdrawn in response to Applicant’s amendment to the claims.
The rejection of claims 34-39 and 51-52 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is withdrawn in response to Applicant’s amendment to the claims.
Claim Rejections/Objections Maintained
In view of the amendment filed on April 21, 2026, the following rejections are maintained.
Double Patenting
7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 34-39 and 51-52 stand rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-33 of US11702467. The rejection is maintained for the reasons of record and the reasons set forth below.
On p. 10 of the response, Applicant request the rejection be held in abeyance until all rejections/objections are resolved.
In response, the rejection of claims 34-39 and 51-52 on the ground of nonstatutory double patenting as being unpatentable over claims 1-33 of US11702467 is maintained until a terminal disclaimer is filed.
The anti-tau-pS413 antibody comprising SEQ ID NOs:33-35 and 53-55 for LCDRs1-3 and HCDRs1-3 (recited in (q) of claim 1, claims 5 and 21 and in (rr) of claim 1, claims 5 and 22), SEQ ID NOs: 36 and 56 for VL and VL (recited in (q) of claim 2 and in (q) of claim 3, claim 6) or SEQ ID NOs: 72 and 71 for HC and LC (claims 7 and 23 and 30) and having SEQ ID NO:58 for a LC constant region (recited in claim 4) and SEQ ID NO:60, 63 or 68 recited in the claims 1-33 of the ‘247 patent meets the limitations recited instant claims, and thus anticipate instant claims. Therefore, Claims 34-39 and 51-52 of instant Application are not patentably distinct from claims 1-33 of the ‘247 patent because claims 34-39 and 51-52 of instant Application anticipated by claims 1-33 of the ‘247 patent.
Accordingly, the rejection of claims 34-39 and 51-52 on the ground of nonstatutory double patenting as being unpatentable over claims 1-33 of US11702467 is maintained.
Conclusion
8. NO CLAIM IS ALLOWED.
9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
US11702467 (under the double patenting rejection) teach the claimed anti-human tau-pS413 antibody comprising the sequences of instant SEQ ID NOs: for HCDR1-3 and LCDR1-3, VH and VL or heavy chain and light chain (see the sequence alignments below).
SEQ ID NO:33-SEQ ID NO:34-SEQ ID NO:35
US-17-355-529-36
Sequence 36, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 36
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VL46_G34A_S28K_S32R_H98Y, VL
Query Match 84.8%; Score 138.3; Length 112;
Best Local Similarity 40.5%;
Matches 32; Conservative 0; Mismatches 0; Indels 47; Gaps 2;
Qy 1 RSSQKIVHRNANTYLE---------------TVSNRFS---------------------- 23
|||||||||||||||| |||||||
Db 24 RSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRV 83
Qy 24 ----------FQGSYLPLT 32
|||||||||
Db 84 EAEDLGVYYCFQGSYLPLT 102
SEQ ID NO:73
US-17-355-529-71
(NOTE: this sequence has 2 duplicates in the database searched)
Sequence 71, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 71
LENGTH: 219
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: V8-AFM-hIgG1 LALA, light chain
Query Match 100.0%; Score 1137; Length 219;
Best Local Similarity 100.0%;
Matches 219; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
SEQ ID NO:36
US-17-355-529-36
Sequence 36, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 36
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VL46_G34A_S28K_S32R_H98Y, VL
Query Match 100.0%; Score 584; Length 112;
Best Local Similarity 100.0%;
Matches 112; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIK 112
||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIK 112
SEQ ID NO:53-SEQ ID NO:54-SEQ ID NO:55
US-17-355-529-56
Sequence 56, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 56
LENGTH: 121
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VH11_K54E_A59V_D68G, VH
Query Match 86.8%; Score 161.4; Length 121;
Best Local Similarity 42.5%;
Matches 34; Conservative 0; Mismatches 0; Indels 46; Gaps 2;
Qy 1 SFALN--------------HIRSETNNYVTFYAASVKG---------------------- 24
||||| |||||||||||||||||||
Db 31 SFALNWVRQAPGKGLEWVGHIRSETNNYVTFYAASVKGRFTVSRDDSQNTAYLQMNSLKT 90
Qy 25 ----------RGPRDSWFGY 34
||||||||||
Db 91 EDTATYYCVRRGPRDSWFGY 110
SEQ ID NO:72
US-17-355-529-72
Sequence 72, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 72
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: V8-AFM-hIgG1 LALA, heavy chain
Query Match 100.0%; Score 2411; Length 451;
Best Local Similarity 100.0%;
Matches 451; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:74
US-17-355-529-74
Sequence 74, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 74
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: V8-AFM-hIgG1 LALA YTE, heavy chain
Query Match 100.0%; Score 2414; Length 451;
Best Local Similarity 100.0%;
Matches 451; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:76
US-17-355-529-76
Sequence 76, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 76
LENGTH: 448
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: V8-AFM-hIgG4, light chain
Query Match 100.0%; Score 2390; Length 448;
Best Local Similarity 100.0%;
Matches 448; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPS 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPS 240
Qy 241 VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNST 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNST 300
Qy 301 YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT 360
Qy 361 KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE 420
Qy 421 GNVFSCSVMHEALHNHYTQKSLSLSLGK 448
||||||||||||||||||||||||||||
Db 421 GNVFSCSVMHEALHNHYTQKSLSLSLGK 448
SEQ ID NO:56
US-17-355-529-56
Sequence 56, US/17355529
Patent No. 11702467
GENERAL INFORMATION
APPLICANT: Merck Sharp & Dohme Corp.
APPLICANT: Baker, Jeanne E.
APPLICANT: Parmentier Batteur, Sophie
APPLICANT: Cheng, Alan C.
APPLICANT: Chen, Ming-Tang
APPLICANT: Hsieh, Chung-Ming
APPLICANT: Mieczkowski, Carl
APPLICANT: Suon, Sokreine
TITLE OF INVENTION: HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE
TITLE OF INVENTION: 413
FILE REFERENCE: 24996-US-NP
CURRENT APPLICATION NUMBER: US/17/355,529
CURRENT FILING DATE: 2021-06-23
PRIOR APPLICATION NUMBER: 63/044,291
PRIOR FILING DATE: 2020-06-25
NUMBER OF SEQ ID NOS: 109
SEQ ID NO 56
LENGTH: 121
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VH11_K54E_A59V_D68G, VH
Query Match 100.0%; Score 644; Length 121;
Best Local Similarity 100.0%;
Matches 121; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 S 121
|
Db 121 S 121
US10556950 teaches a humanized anti-tau antibody comprising a heavy chain (HC) and a light chain (LC), wherein HC comprises the amino acid sequence of SEQ ID NO:145, which is 99.4% identical to instant SEQ ID NO:72 and wherein the HC comprises HCDR1 of instant SEQ ID NO:53 and HCDR3 of instant SEQ ID NO: 55 but does not comprises HCDR2 of instant SEQ ID NO:54, and wherein the LC comprises the amino acid sequence of SEQ ID NO:166, which is 98.6 identical to instant SEQ ID NO:73 and wherein the LC which comprises LCDR2 of instant SEQ ID NO:34 but does not comprise LCDR1 of instant SEQ ID NO:33 and LCDR3 of instant SEQ ID NO:35 (see the sequence alignment below).
SEQ ID NO:53-SEQ ID NO:54-SEQ ID NO:55
US-15-906-773A-134
(NOTE: this sequence has 2 duplicates in the database searched)
Sequence 134, US/15906773A
Patent No. 10556950
GENERAL INFORMATION
APPLICANT: EGUCHI, Hiroshi
APPLICANT: MURAKAMI, Takashi
APPLICANT: NAMIKI, Naoko
APPLICANT: TANOKURA, Akira
APPLICANT: BAKER, Jeanne E.
APPLICANT: PARMENTIER BATTEUR, Sophie
APPLICANT: JABLONSKI, Angela Marie
APPLICANT: MALASHOCK, Daniel Stephen
APPLICANT: MIECZKOWSKI, Carl
APPLICANT: RAGHUNATHAN, Gopalan (Raghu)
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS
FILE REFERENCE: 063785-06-5002-WO01 and 5002-US01
CURRENT APPLICATION NUMBER: US/15/906,773A
CURRENT FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 134
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Humanized variant heavy chain, H2
Query Match 82.5%; Score 153.4; Length 451;
Best Local Similarity 40.0%;
Matches 32; Conservative 1; Mismatches 1; Indels 46; Gaps 2;
Qy 1 SFALN--------------HIRSETNNYVTFYAASVKG---------------------- 24
||||| ||||:|||| |||||||||
Db 31 SFALNWVRQAPGKGLEWVGHIRSKTNNYATFYAASVKGRFTVSRDDSKNTAYLQMNSLKT 90
Qy 25 ----------RGPRDSWFGY 34
||||||||||
Db 91 EDTATYYCVRRGPRDSWFGY 110
SEQ ID NO:72
US-15-906-773A-145
(NOTE: this sequence has 2 duplicates in the database searched)
Sequence 145, US/15906773A
Patent No. 10556950
GENERAL INFORMATION
APPLICANT: EGUCHI, Hiroshi
APPLICANT: MURAKAMI, Takashi
APPLICANT: NAMIKI, Naoko
APPLICANT: TANOKURA, Akira
APPLICANT: BAKER, Jeanne E.
APPLICANT: PARMENTIER BATTEUR, Sophie
APPLICANT: JABLONSKI, Angela Marie
APPLICANT: MALASHOCK, Daniel Stephen
APPLICANT: MIECZKOWSKI, Carl
APPLICANT: RAGHUNATHAN, Gopalan (Raghu)
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS
FILE REFERENCE: 063785-06-5002-WO01 and 5002-US01
CURRENT APPLICATION NUMBER: US/15/906,773A
CURRENT FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 145
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: H11 Human_IgG1_L234A_L235A
Query Match 99.4%; Score 2396; Length 451;
Best Local Similarity 99.3%;
Matches 448; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKDRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:33-SEQ ID NO:34-SEQ ID NO:35
US-15-906-773A-105
(NOTE: this sequence has 2 duplicates in the database searched)
Sequence 105, US/15906773A
Patent No. 10556950
GENERAL INFORMATION
APPLICANT: EGUCHI, Hiroshi
APPLICANT: MURAKAMI, Takashi
APPLICANT: NAMIKI, Naoko
APPLICANT: TANOKURA, Akira
APPLICANT: BAKER, Jeanne E.
APPLICANT: PARMENTIER BATTEUR, Sophie
APPLICANT: JABLONSKI, Angela Marie
APPLICANT: MALASHOCK, Daniel Stephen
APPLICANT: MIECZKOWSKI, Carl
APPLICANT: RAGHUNATHAN, Gopalan (Raghu)
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS
FILE REFERENCE: 063785-06-5002-WO01 and 5002-US01
CURRENT APPLICATION NUMBER: US/15/906,773A
CURRENT FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 105
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Ta1505-VL46_G34A, VL
Query Match 75.0%; Score 122.3; Length 112;
Best Local Similarity 36.7%;
Matches 29; Conservative 1; Mismatches 2; Indels 47; Gaps 2;
Qy 1 RSSQKIVHRNANTYLE---------------TVSNRFS---------------------- 23
|||| ||| ||||||| |||||||
Db 24 RSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRV 83
Qy 24 ----------FQGSYLPLT 32
||||:||||
Db 84 EAEDLGVYYCFQGSHLPLT 102
SEQ ID NO:73
US-15-906-773A-166
(NOTE: this sequence has 2 duplicates in the database searched)
Sequence 166, US/15906773A
Patent No. 10556950
GENERAL INFORMATION
APPLICANT: EGUCHI, Hiroshi
APPLICANT: MURAKAMI, Takashi
APPLICANT: NAMIKI, Naoko
APPLICANT: TANOKURA, Akira
APPLICANT: BAKER, Jeanne E.
APPLICANT: PARMENTIER BATTEUR, Sophie
APPLICANT: JABLONSKI, Angela Marie
APPLICANT: MALASHOCK, Daniel Stephen
APPLICANT: MIECZKOWSKI, Carl
APPLICANT: RAGHUNATHAN, Gopalan (Raghu)
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS
FILE REFERENCE: 063785-06-5002-WO01 and 5002-US01
CURRENT APPLICATION NUMBER: US/15/906,773A
CURRENT FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 166
LENGTH: 219
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VL46_G34A kappa
Query Match 98.6%; Score 1121; Length 219;
Best Local Similarity 98.6%;
Matches 216; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||| ||| ||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
|||||||||||||||||||||||||||||||||||||:||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
US10894829 teaches a humanized anti-tau antibody comprising a heavy chain (HC) and a light chain (LC), wherein HC comprises the amino acid sequence of SEQ ID NO:145, which is 99.4% identical to instant SEQ ID NO:72 and wherein the HC comprises HCDR1 of instant SEQ ID NO:53 and HCDR3 of instant SEQ ID NO: 55 but does not comprises HCDR2 of instant SEQ ID NO:54, and wherein the LC comprises the amino acid sequence of SEQ ID NO:166, which is 98.6% identical to instant SEQ ID NO:73 and wherein the LC which comprises LCDR2 of instant SEQ ID NO:34 but does not comprise LCDR1 of instant SEQ ID NO:33 and LCDR3 of instant SEQ ID NO:35 (see the sequence alignment below).
SEQ ID NO:72
Sequence 145, US/16746725A
Patent No. 10894829
GENERAL INFORMATION
APPLICANT: TEIJIN PHARMA LIMITED
APPLICANT: MERCK SHARP & DOHME CORP.
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR
TITLE OF INVENTION: TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
FILE REFERENCE: 14463-026-999
CURRENT APPLICATION NUMBER: US/16/746,725A
CURRENT FILING DATE: 2020-01-17
PRIOR APPLICATION NUMBER: US 15/906,773
PRIOR FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 145
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: H11 Human_IgG1_L234A_L235A
Query Match 99.4%; Score 2396; Length 451;
Best Local Similarity 99.3%;
Matches 448; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKDRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:73
Sequence 166, US/16746725A
Patent No. 10894829
GENERAL INFORMATION
APPLICANT: TEIJIN PHARMA LIMITED
APPLICANT: MERCK SHARP & DOHME CORP.
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR
TITLE OF INVENTION: TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
FILE REFERENCE: 14463-026-999
CURRENT APPLICATION NUMBER: US/16/746,725A
CURRENT FILING DATE: 2020-01-17
PRIOR APPLICATION NUMBER: US 15/906,773
PRIOR FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 166
LENGTH: 219
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VL46_G34A kappa
Query Match 98.6%; Score 1121; Length 219;
Best Local Similarity 98.6%;
Matches 216; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||| ||| ||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
|||||||||||||||||||||||||||||||||||||:||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
US11739143 teaches a humanized anti-tau antibody comprising a heavy chain (HC) and a light chain (LC), wherein HC comprises the amino acid sequence of SEQ ID NO:145, which is 99.4% identical to instant SEQ ID NO:72 and wherein the HC comprises HCDR1 of instant SEQ ID NO:53 and HCDR3 of instant SEQ ID NO: 55 but does not comprises HCDR2 of instant SEQ ID NO:54, and wherein the LC comprises the amino acid sequence of SEQ ID NO:166, which is 98.6 identical to instant SEQ ID NO:73 and wherein the LC which comprises LCDR2 of instant SEQ ID NO:34 but does not comprise LCDR1 of instant SEQ ID NO:33 and LCDR3 of instant SEQ ID NO:35 (see the sequence alignment below).
SEQ ID NO:72
Sequence 145, US/17122325A
Patent No. 11739143
GENERAL INFORMATION
APPLICANT: TEIJIN PHARMA LIMITED
APPLICANT: MERCK SHARP & DOHME CORP.
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR
TITLE OF INVENTION: TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
FILE REFERENCE: 14463-027-999
CURRENT APPLICATION NUMBER: US/17/122,325A
CURRENT FILING DATE: 2020-12-15
PRIOR APPLICATION NUMBER: US 16/746,725
PRIOR FILING DATE: 2020-01-17
PRIOR APPLICATION NUMBER: US 15/906,773
PRIOR FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 145
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: H11 Human_IgG1_L234A_L235A
Query Match 99.4%; Score 2396; Length 451;
Best Local Similarity 99.3%;
Matches 448; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKDRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:73
Sequence 166, US/17122325A
Patent No. 11739143
GENERAL INFORMATION
APPLICANT: TEIJIN PHARMA LIMITED
APPLICANT: MERCK SHARP & DOHME CORP.
TITLE OF INVENTION: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE
TITLE OF INVENTION: DISORDERS, PROCESS FOR PRODUCING THE SAME, AND AGENT FOR
TITLE OF INVENTION: TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME
FILE REFERENCE: 14463-027-999
CURRENT APPLICATION NUMBER: US/17/122,325A
CURRENT FILING DATE: 2020-12-15
PRIOR APPLICATION NUMBER: US 16/746,725
PRIOR FILING DATE: 2020-01-17
PRIOR APPLICATION NUMBER: US 15/906,773
PRIOR FILING DATE: 2018-02-27
PRIOR APPLICATION NUMBER: JP 2017-035594
PRIOR FILING DATE: 2017-02-27
NUMBER OF SEQ ID NOS: 185
SEQ ID NO 166
LENGTH: 219
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: VL46_G34A kappa
Query Match 98.6%; Score 1121; Length 219;
Best Local Similarity 98.6%;
Matches 216; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||| ||| ||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
|||||||||||||||||||||||||||||||||||||:||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
WO2018154390 teaches an anti-pSer413 tau antibody mAb-pPT2 comprising a heavy chain (HC) and a light chain (LC), wherein HC comprises the amino acid sequence of SEQ ID NO:145, which is 99.4% identical to instant SEQ ID NO:72 and wherein the HC comprises HCDR1 of instant SEQ ID NO:53 and HCDR3 of instant SEQ ID NO: 55 but does not comprises HCDR2 of instant SEQ ID NO:54, and wherein the LC comprises the amino acid sequence of SEQ ID NO:166, which is 98.6 identical to instant SEQ ID NO:73 and wherein the LC which comprises LCDR2 of instant SEQ ID NO:34 but does not comprise LCDR1 of instant SEQ ID NO:33 and LCDR3 of instant SEQ ID NO:35 (see the sequence alignment below).
SEQ ID NO:72
BFQ05739
(NOTE: this sequence has 1 duplicate in the database searched)
ID BFQ05739 standard; protein; 451 AA.
XX
AC BFQ05739;
XX
DT 18-OCT-2018 (first entry)
XX
DE Anti-pSer413 tau antibody mAb-aPT2 heavy chain, SEQ ID 145.
XX
KW Immunoglobulin G1; Tau protein; alzheimers disease; antibody production;
KW antibody therapy; calcification; degeneration; dementia;
KW frontotemporal dementia; fusion protein; heavy chain; metabolic-gen.;
KW monoclonal antibody; neuroprotective; nootropic; parkinsonism;
KW progressive supranuclear palsy; prophylactic to disease; therapeutic.
XX
OS Homo sapiens.
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Region 30..35
FT /label= CDR1
FT Region 50..68
FT /label= CDR2
FT Region 101..110
FT /label= CDR3
XX
CC PN WO2018154390-A1.
XX
CC PD 30-AUG-2018.
XX
CC PF 27-FEB-2018; 2018WO-IB000249.
XX
PR 27-FEB-2017; 2017JP-00035594.
XX
CC PA (TEIJ ) TEIJIN PHARMA LTD.
CC PA (MERI ) MERCK SHARP & DOHME CORP.
XX
CC PI Eguchi H, Murakami T, Namiki N, Tanokura A, Baker JE;
CC PI Parmentier Batteur S, Jablonski AM, Malashock DS, Mieczkowski C;
CC PI Raghunathan GR;
XX
DR WPI; 2018-67626E/60.
XX
CC PT New anti-pSer413 tau antibody used for treating tauopathy e.g.
CC PT Alzheimer's disease and improving cognitive function in human, comprises
CC PT heavy variable domain and light variable domain comprising specific amino
CC PT acid sequences.
XX
CC PS Claim 8; SEQ ID NO 145; 143pp; English.
XX
CC The present invention relates to a novel humanized anti-pSer413 tau
CC antibody useful for treating tauopathy e.g., Alzheimer's disease and
CC improving cognitive function in human. The invention further relates to:
CC (1) a nucleic acid composition; (2) an expression vector; (3) a host cell
CC ; (4) a method for producing anti-pSer413 t antibody; and (5) a method
CC for treating tauopathy in a subject. The antibody of the invention is
CC also used for preventing tauopathy includes corticobasal degeneration,
CC progressive supranuclear palsy, Pick's disease, argyrophilic grain
CC dementia, multiple system tauopathy with presenile dementia,
CC frontotemporal dementia and parkinsonism linked to chromosome 17,
CC dementia with neurofibrillary tangles, diffuse neurofibrillary tangle
CC with calcification. The present sequence represents an anti-pSer413
CC antibody heavy chain comprising IgG1 backbone sequence, used in the
CC invention for preparing the humanized anti-pSer413 tau antibody for
CC treating tauopathy.
XX
SQ Sequence 451 AA;
Query Match 99.4%; Score 2396; Length 451;
Best Local Similarity 99.3%;
Matches 448; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKDRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:73
BFQ05760
(NOTE: this sequence has 2 duplicates in the database searched)
ID BFQ05760 standard; protein; 219 AA.
XX
AC BFQ05760;
XX
DT 18-OCT-2018 (first entry)
XX
DE Anti-pSer413 tau VL46_G34A kappa light chian, SEQ 166.
XX
KW Tau protein; alzheimers disease; antibody; antibody production;
KW antibody therapy; calcification; degeneration; dementia;
KW frontotemporal dementia; light chian; metabolic-gen.; mutein;
KW neuroprotective; nootropic; parkinsonism; progressive supranuclear palsy;
KW prophylactic to disease; therapeutic.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Region 24..39
FT /label= CDR1
FT Region 55..62
FT /label= CDR2
FT Region 94..102
FT /label= CDR3
XX
CC PN WO2018154390-A1.
XX
CC PD 30-AUG-2018.
XX
CC PF 27-FEB-2018; 2018WO-IB000249.
XX
PR 27-FEB-2017; 2017JP-00035594.
XX
CC PA (TEIJ ) TEIJIN PHARMA LTD.
CC PA (MERI ) MERCK SHARP & DOHME CORP.
XX
CC PI Eguchi H, Murakami T, Namiki N, Tanokura A, Baker JE;
CC PI Parmentier Batteur S, Jablonski AM, Malashock DS, Mieczkowski C;
CC PI Raghunathan GR;
XX
DR WPI; 2018-67626E/60.
XX
CC PT New anti-pSer413 tau antibody used for treating tauopathy e.g.
CC PT Alzheimer's disease and improving cognitive function in human, comprises
CC PT heavy variable domain and light variable domain comprising specific amino
CC PT acid sequences.
XX
CC PS Claim 9; SEQ ID NO 166; 143pp; English.
XX
CC The present invention relates to a novel humanized anti-pSer413 tau
CC antibody useful for treating tauopathy e.g., Alzheimer's disease and
CC improving cognitive function in human. The invention further relates to:
CC (1) a nucleic acid composition; (2) an expression vector; (3) a host cell
CC ; (4) a method for producing anti-pSer413 t antibody; and (5) a method
CC for treating tauopathy in a subject. The antibody of the invention is
CC also used for preventing tauopathy includes corticobasal degeneration,
CC progressive supranuclear palsy, Pick's disease, argyrophilic grain
CC dementia, multiple system tauopathy with presenile dementia,
CC frontotemporal dementia and parkinsonism linked to chromosome 17,
CC dementia with neurofibrillary tangles, diffuse neurofibrillary tangle
CC with calcification. The present sequence represents an anti-pSer413
CC antibody light chain, used in the invention for preparing the humanized
CC anti-pSer413 tau antibody for treating tauopathy.
XX
SQ Sequence 219 AA;
Query Match 98.6%; Score 1121; Length 219;
Best Local Similarity 98.6%;
Matches 216; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||| ||| ||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
|||||||||||||||||||||||||||||||||||||:||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
SEQ ID NO:56
BFQ05728
(NOTE: this sequence has 2 duplicates in the database searched)
ID BFQ05728 standard; protein; 451 AA.
XX
AC BFQ05728;
XX
DT 18-OCT-2018 (first entry)
XX
DE Humanized anti-tau antibody heavy chain variant 10 (H2), SEQ ID 134.
XX
KW Tau protein; alzheimers disease; antibody production; antibody therapy;
KW calcification; degeneration; dementia; frontotemporal dementia;
KW heavy chain; humanized antibody; metabolic-gen.; neuroprotective;
KW nootropic; parkinsonism; progressive supranuclear palsy;
KW prophylactic to disease; therapeutic.
XX
OS Homo sapiens.
OS Mus musculus.
OS Chimeric.
XX
CC PN WO2018154390-A1.
XX
CC PD 30-AUG-2018.
XX
CC PF 27-FEB-2018; 2018WO-IB000249.
XX
PR 27-FEB-2017; 2017JP-00035594.
XX
CC PA (TEIJ ) TEIJIN PHARMA LTD.
CC PA (MERI ) MERCK SHARP & DOHME CORP.
XX
CC PI Eguchi H, Murakami T, Namiki N, Tanokura A, Baker JE;
CC PI Parmentier Batteur S, Jablonski AM, Malashock DS, Mieczkowski C;
CC PI Raghunathan GR;
XX
DR WPI; 2018-67626E/60.
XX
CC PT New anti-pSer413 tau antibody used for treating tauopathy e.g.
CC PT Alzheimer's disease and improving cognitive function in human, comprises
CC PT heavy variable domain and light variable domain comprising specific amino
CC PT acid sequences.
XX
CC PS Example 6; SEQ ID NO 134; 143pp; English.
XX
CC The present invention relates to a novel humanized anti-pSer413 tau
CC antibody useful for treating tauopathy e.g., Alzheimer's disease and
CC improving cognitive function in human. The invention further relates to:
CC (1) a nucleic acid composition; (2) an expression vector; (3) a host cell
CC ; (4) a method for producing anti-pSer413 t antibody; and (5) a method
CC for treating tauopathy in a subject. The antibody of the invention is
CC also used for preventing tauopathy includes corticobasal degeneration,
CC progressive supranuclear palsy, Pick's disease, argyrophilic grain
CC dementia, multiple system tauopathy with presenile dementia,
CC frontotemporal dementia and parkinsonism linked to chromosome 17,
CC dementia with neurofibrillary tangles, diffuse neurofibrillary tangle
CC with calcification. The present sequence represents a humanized anti-tau
CC antibody heavy chain variant, used in the invention for treating
CC tauopathy.
XX
SQ Sequence 451 AA;
Query Match 98.1%; Score 632; Length 451;
Best Local Similarity 97.5%;
Matches 118; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
|||||||||||||||||:||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKGRFTVSRDDSKNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 S 121
|
Db 121 S 121
WO2018154392 teaches an anti-tau antibody comprising a heavy chain (HC) and a light chain (LC), wherein HC comprises the amino acid sequence of SEQ ID NO:145, which is 99.4% identical to instant SEQ ID NO:72 and wherein the HC comprises HCDR1 of instant SEQ ID NO:53 and HCDR3 of instant SEQ ID NO: 55 but does not comprises HCDR2 of instant SEQ ID NO:54, and wherein the LC comprises the amino acid sequence of SEQ ID NO:166, which is 98.6 identical to instant SEQ ID NO:73 and wherein the LC which comprises LCDR2 of instant SEQ ID NO:34 but does not comprise LCDR1 of instant SEQ ID NO:33 and LCDR3 of instant SEQ ID NO:35 (see the sequence alignment below).
SEQ ID NO:72
ID BFQ05927 standard; protein; 451 AA.
XX
AC BFQ05927;
XX
DT 18-OCT-2018 (first entry)
XX
DE Anti-pSer413 tau antibody mAb-aPT2 heavy chain, SEQ ID 145.
XX
KW Immunoglobulin G1; Tau protein; alzheimers disease; antibody;
KW antibody production; antibody therapy; calcification; degeneration;
KW dementia; frontotemporal dementia; fusion protein; heavy chain;
KW metabolic-gen.; neuroprotective; nootropic; parkinsonism;
KW progressive supranuclear palsy; prophylactic to disease; therapeutic.
XX
OS Homo sapiens.
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Region 30..35
FT /label= CDR1
FT Region 50..68
FT /label= CDR2
FT Region 101..110
FT /label= CDR3
XX
CC PN WO2018154392-A1.
XX
CC PD 30-AUG-2018.
XX
CC PF 25-FEB-2018; 2018WO-IB000267.
XX
PR 27-FEB-2017; 2017JP-00035594.
XX
CC PA (TEIJ ) TEIJIN PHARMA LTD.
CC PA (MERI ) MERCK SHARP & DOHME CORP.
XX
CC PI Eguchi H, Murakami T, Namiki N, Tanokura A, Baker JE;
CC PI Parmentier BS, Jablonski AM, Malashock DS, Mieczkowski C;
CC PI Raghunathan GR;
XX
DR WPI; 2018-67626C/61.
XX
CC PT New humanized antibody that causes antigen-antibody reaction with tau-
CC PT protein or peptide phosphorylated on amino acid residue corresponding to
CC PT serine of specific amino acid sequence used to treat or prevent dementia
CC PT e.g. Alzheimer's disease.
XX
CC PS Claim 8; SEQ ID NO 145; 138pp; English.
XX
CC The present invention relates to a novel humanized anti-pSer413 tau
CC antibody useful for treating tauopathy e.g., Alzheimer's disease and
CC improving cognitive function in human. The invention further relates to:
CC (1) a nucleic acid composition; (2) an expression vector; (3) a host cell
CC ; (4) a method for producing anti-pSer413 t antibody; and (5) a method
CC for treating tauopathy in a subject. The antibody of the invention is
CC also used for preventing tauopathy includes corticobasal degeneration,
CC progressive supranuclear palsy, Pick's disease, argyrophilic grain
CC dementia, multiple system tauopathy with presenile dementia,
CC frontotemporal dementia and parkinsonism linked to chromosome 17,
CC dementia with neurofibrillary tangles, diffuse neurofibrillary tangle
CC with calcification. The present sequence represents an anti-pSer413
CC antibody heavy chain comprising IgG1 backbone sequence, used in the
CC invention for preparing the humanized anti-pSer413 tau antibody for
CC treating tauopathy.
XX
SQ Sequence 451 AA;
Query Match 99.4%; Score 2396; Length 451;
Best Local Similarity 99.3%;
Matches 448; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKDRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:73
ID BFQ05948 standard; protein; 219 AA.
XX
AC BFQ05948;
XX
DT 18-OCT-2018 (first entry)
XX
DE Anti-pSer413 tau VL46_G34A kappa light chian, SEQ 166.
XX
KW Tau protein; alzheimers disease; antibody; antibody production;
KW antibody therapy; calcification; degeneration; dementia;
KW frontotemporal dementia; light chian; metabolic-gen.; neuroprotective;
KW nootropic; parkinsonism; progressive supranuclear palsy;
KW prophylactic to disease; therapeutic.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Region 24..39
FT /label= CDR1
FT Region 55..62
FT /label= CDR2
FT Region 94..102
FT /label= CDR3
XX
CC PN WO2018154392-A1.
XX
CC PD 30-AUG-2018.
XX
CC PF 25-FEB-2018; 2018WO-IB000267.
XX
PR 27-FEB-2017; 2017JP-00035594.
XX
CC PA (TEIJ ) TEIJIN PHARMA LTD.
CC PA (MERI ) MERCK SHARP & DOHME CORP.
XX
CC PI Eguchi H, Murakami T, Namiki N, Tanokura A, Baker JE;
CC PI Parmentier BS, Jablonski AM, Malashock DS, Mieczkowski C;
CC PI Raghunathan GR;
XX
DR WPI; 2018-67626C/61.
XX
CC PT New humanized antibody that causes antigen-antibody reaction with tau-
CC PT protein or peptide phosphorylated on amino acid residue corresponding to
CC PT serine of specific amino acid sequence used to treat or prevent dementia
CC PT e.g. Alzheimer's disease.
XX
CC PS Claim 9; SEQ ID NO 166; 138pp; English.
XX
CC The present invention relates to a novel humanized anti-pSer413 tau
CC antibody useful for treating tauopathy e.g., Alzheimer's disease and
CC improving cognitive function in human. The invention further relates to:
CC (1) a nucleic acid composition; (2) an expression vector; (3) a host cell
CC ; (4) a method for producing anti-pSer413 t antibody; and (5) a method
CC for treating tauopathy in a subject. The antibody of the invention is
CC also used for preventing tauopathy includes corticobasal degeneration,
CC progressive supranuclear palsy, Pick's disease, argyrophilic grain
CC dementia, multiple system tauopathy with presenile dementia,
CC frontotemporal dementia and parkinsonism linked to chromosome 17,
CC dementia with neurofibrillary tangles, diffuse neurofibrillary tangle
CC with calcification. The present sequence represents an anti-pSer413
CC antibody light chain, used in the invention for preparing the humanized
CC anti-pSer413 tau antibody for treating tauopathy.
XX
SQ Sequence 219 AA;
Query Match 98.6%; Score 1121; Length 219;
Best Local Similarity 98.6%;
Matches 216; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||| ||| ||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
|||||||||||||||||||||||||||||||||||||:||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
WO2020223279 teaches an anti-tau antibody comprising a heavy chain (HC) and a light chain (LC), wherein HC comprises the amino acid sequence of SEQ ID NO: 13489, which is 99.0% identical to instant SEQ ID NO:72 and wherein the HC comprises HCDR1 of instant SEQ ID NO:53 and HCDR3 of instant SEQ ID NO: 55 but does not comprises HCDR2 of instant SEQ ID NO:54, and wherein the LC comprises the amino acid sequence of SEQ ID NO: 13500, which is 98.6 identical to instant SEQ ID NO:73 and wherein the LC which comprises LCDR2 of instant SEQ ID NO:34 but does not comprise LCDR1 of instant SEQ ID NO:33 and LCDR3 of instant SEQ ID NO:35 (see the sequence alignment below).
SEQ ID NO:72
ID BIM12081 standard; protein; 451 AA.
XX
AC BIM12081;
XX
DT 10-DEC-2020 (first entry)
XX
DE Tau associated disease antibody amino acid, SEQ ID 13489.
XX
KW antibody; antibody therapy; prophylactic to disease; therapeutic;
KW vectorized antibody.
XX
OS Synthetic.
XX
CC PN WO2020223279-A1.
XX
CC PD 05-NOV-2020.
XX
CC PF 29-APR-2020; 2020WO-US030360.
XX
PR 29-APR-2019; 2019US-0839891P.
PR 12-JUN-2019; 2019US-0860295P.
PR 28-OCT-2019; 2019US-0926706P.
PR 30-MAR-2020; 2020US-0002008P.
PR 30-MAR-2020; 2020US-0002011P.
XX
CC PA (VOYA-) VOYAGER THERAPEUTICS INC.
XX
CC PI Hou J, Shu Y, Carter T, Sah DW, Yen P, Ward DT, Crimins JL;
XX
DR WPI; 2020-A7091D/097.
XX
CC PT Adeno-associated viral (AAV) particle for treating influenza, comprises
CC PT capsid and viral genome comprising inverted terminal repeat (ITR)
CC PT sequence region, promoter sequence region, polyA sequence region, and
CC PT payload region.
XX
CC PS Claim 31; SEQ ID NO 13489; 824pp; English.
XX
CC The present invention relates to vectorized antibodies (vAB), and more
CC specifically, to an adeno-associated viral (AAV) particle for treating a
CC disease or disorder. The AAV particle comprises a capsid and a viral
CC genome comprising a 5' inverted terminal repeat (ITR) sequence region, at
CC least one promoter sequence region, a polyA sequence region, a 3'-ITR
CC sequence region, and at least one payload region comprising a 1st nucleic
CC acid sequence encoding an antibody, an antibody fragment or an antibody
CC variant. The AAV particle is useful for producing an antibody in a
CC subject; for expressing an antibody in a cell or tissue; and for
CC preparing pharmaceutical composition for preventing or treating disease
CC or disorder selected from diseases caused by John Cunningham virus (JCV),
CC influenza, hepatitis A, hepatitis B, hepatitis D, hepatitis E,
CC respiratory syncytial virus (RSV), herpes simplex virus 1, herpes simplex
CC virus 2, human cytomegalovirus, Epstein-Barr virus, varicella zoster
CC virus, coronavirus, Poxvirus, Enterovirus 71, rubella virus, human
CC papillomavirus, Pseudomonas aeruginosa, Streptococcus bacteria,
CC Staphylococcus bacteria, Clostridium tetani, Bordetella, Mycobacterium,
CC Francisella tularensis, Toxoplasma gondii, Candida yeast, ricin, Bacillus
CC anthracis, shiga toxin, shiga-like toxin, botulinum toxins, chikungunya
CC virus, dengue virus, Trypanosoma cruzi, rabies virus, Plasmodium
CC falciparum, ebola virus, Marburg virus, West Nile virus, Yellow Fever
CC virus, Japanese encephalitis virus, St. Louis encephalitis virus,
CC rotavirus, Norwalk virus, Campylobacter jejuni, Clostridium difficile,
CC Entamoeba histolytica, Helicobacter pylori, and enterotoxin B,
CC Parkinson's disease, dementia with Lewy Bodies, multiple system atrophy,
CC decreased muscle mass, decreased muscle strength, decreased muscle
CC function, spinal muscular atrophy, Alzheimer's disease, Huntington's
CC disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke,
CC migraine, pain, neuropathies, psychiatric disorders, cancer, ocular
CC diseases, systemic diseases of the blood, systemic diseases of the heart,
CC systemic diseases of the bone, immune system, autoimmune disease,
CC inflammation disorders and inflammation.
XX
SQ Sequence 451 AA;
Query Match 99.0%; Score 2386; Length 451;
Best Local Similarity 98.9%;
Matches 446; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
Qy 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSETNNYVT 60
|||||||||||||||||||||||||||||||||||||||||||||||||||||:|||| |
Db 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFALNWVRQAPGKGLEWVGHIRSKTNNYAT 60
Qy 61 FYAASVKGRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 FYAASVKDRFTVSRDDSQNTAYLQMNSLKTEDTATYYCVRRGPRDSWFGYWGQGTLVTVS 120
Qy 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS 180
Qy 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |
Db 181 SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG 240
Qy 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 300
Qy 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD 360
Qy 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 420
Qy 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
|||||||||||||||||||||||||||||||
Db 421 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 451
SEQ ID NO:73
ID BIM12092 standard; protein; 219 AA.
XX
AC BIM12092;
XX
DT 10-DEC-2020 (first entry)
XX
DE Tau associated disease antibody amino acid, SEQ ID 13500.
XX
KW antibody; antibody therapy; prophylactic to disease; therapeutic;
KW vectorized antibody.
XX
OS Synthetic.
XX
CC PN WO2020223279-A1.
XX
CC PD 05-NOV-2020.
XX
CC PF 29-APR-2020; 2020WO-US030360.
XX
PR 29-APR-2019; 2019US-0839891P.
PR 12-JUN-2019; 2019US-0860295P.
PR 28-OCT-2019; 2019US-0926706P.
PR 30-MAR-2020; 2020US-0002008P.
PR 30-MAR-2020; 2020US-0002011P.
XX
CC PA (VOYA-) VOYAGER THERAPEUTICS INC.
XX
CC PI Hou J, Shu Y, Carter T, Sah DW, Yen P, Ward DT, Crimins JL;
XX
DR WPI; 2020-A7091D/097.
XX
CC PT Adeno-associated viral (AAV) particle for treating influenza, comprises
CC PT capsid and viral genome comprising inverted terminal repeat (ITR)
CC PT sequence region, promoter sequence region, polyA sequence region, and
CC PT payload region.
XX
CC PS Claim 31; SEQ ID NO 13500; 824pp; English.
XX
CC The present invention relates to vectorized antibodies (vAB), and more
CC specifically, to an adeno-associated viral (AAV) particle for treating a
CC disease or disorder. The AAV particle comprises a capsid and a viral
CC genome comprising a 5' inverted terminal repeat (ITR) sequence region, at
CC least one promoter sequence region, a polyA sequence region, a 3'-ITR
CC sequence region, and at least one payload region comprising a 1st nucleic
CC acid sequence encoding an antibody, an antibody fragment or an antibody
CC variant. The AAV particle is useful for producing an antibody in a
CC subject; for expressing an antibody in a cell or tissue; and for
CC preparing pharmaceutical composition for preventing or treating disease
CC or disorder selected from diseases caused by John Cunningham virus (JCV),
CC influenza, hepatitis A, hepatitis B, hepatitis D, hepatitis E,
CC respiratory syncytial virus (RSV), herpes simplex virus 1, herpes simplex
CC virus 2, human cytomegalovirus, Epstein-Barr virus, varicella zoster
CC virus, coronavirus, Poxvirus, Enterovirus 71, rubella virus, human
CC papillomavirus, Pseudomonas aeruginosa, Streptococcus bacteria,
CC Staphylococcus bacteria, Clostridium tetani, Bordetella, Mycobacterium,
CC Francisella tularensis, Toxoplasma gondii, Candida yeast, ricin, Bacillus
CC anthracis, shiga toxin, shiga-like toxin, botulinum toxins, chikungunya
CC virus, dengue virus, Trypanosoma cruzi, rabies virus, Plasmodium
CC falciparum, ebola virus, Marburg virus, West Nile virus, Yellow Fever
CC virus, Japanese encephalitis virus, St. Louis encephalitis virus,
CC rotavirus, Norwalk virus, Campylobacter jejuni, Clostridium difficile,
CC Entamoeba histolytica, Helicobacter pylori, and enterotoxin B,
CC Parkinson's disease, dementia with Lewy Bodies, multiple system atrophy,
CC decreased muscle mass, decreased muscle strength, decreased muscle
CC function, spinal muscular atrophy, Alzheimer's disease, Huntington's
CC disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke,
CC migraine, pain, neuropathies, psychiatric disorders, cancer, ocular
CC diseases, systemic diseases of the blood, systemic diseases of the heart,
CC systemic diseases of the bone, immune system, autoimmune disease,
CC inflammation disorders and inflammation.
XX
SQ Sequence 219 AA;
Query Match 98.6%; Score 1121; Length 219;
Best Local Similarity 98.6%;
Matches 216; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1 DIVMTQSPLSLPVTLGEPASISCRSSQKIVHRNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
||||||||||||||||||||||||||| ||| ||||||||||||||||||||||||||||
Db 1 DIVMTQSPLSLPVTLGEPASISCRSSQSIVHSNANTYLEWYLQKPGQSPQLLIYTVSNRF 60
Qy 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSYLPLTFGGGTKVEIKRTVAAPSV 120
|||||||||||||||||||||||||||||||||||||:||||||||||||||||||||||
Db 61 SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHLPLTFGGGTKVEIKRTVAAPSV 120
Qy 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL 180
Qy 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
|||||||||||||||||||||||||||||||||||||||
Db 181 SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 219
10. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
11, Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANG-YU WANG whose telephone number is (571)272-4521. The examiner can normally be reached Monday-Thursday, 7:00am-5:00pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Chang-Yu Wang
May 11, 2026
/CHANG-YU WANG/Primary Examiner, Art Unit 1675
Prosecution Insights